As BACE1 is known to be significantly increased in the brains of AD patients, as well as in their CSF (Stozická et al., 2007; Evin and Hince, 2013), we suggest that miR-200a-3p could act as a potential peripheral biomarker together with BACE1 for AD diagnosis and/or treatment. Here, BACE1 is linked to Alzheimer disease.